Sugi Predict

Sugi Predict / Compounds / Ternidazole

Ternidazole

Ternidazole

SCHEMBL2108944

Cc1ncc([N+](=O)[O-])n1CCCO

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.82
▸ ALDH1A1 P00352 3/20 0.82
▸ MAPK1 P28482 2/20 0.82
▸ THRB P10828 1/20 0.82
▸ TSHR P16473 1/20 0.82
▸ CA1 P00915 5/20 0.61
▸ CA2 P00918 5/20 0.61
▸ CA9 Q16790 5/20 0.61
▸ SMN1; SMN2 Q16637 1/20 0.61
▸ GLA P06280 1/20 0.60
▸ ATM Q13315 1/20 0.60
▸ CA12 O43570 4/20 0.57
▸ CHRM1 P11229 1/20 0.56
▸ GAA P10253 1/20 0.54
▸ KMT2A Q03164 2/20 0.52
▸ MEN1 O00255 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ EGFR P00533 2/20 0.49
▸ ERBB2 P04626 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Metronidazole SCHEMBL23042 0.90 LMNA (1.00) LMNAALDH1A1MAPK1THRBTSHR
Metronidazole SCHEMBL5313560 0.90 LMNA (1.00) LMNAALDH1A1MAPK1THRBTSHR
Metronidazole SCHEMBL31108924 0.90 LMNA (1.00) LMNAALDH1A1MAPK1THRBTSHR
Metronidazole SCHEMBL2221140 0.90 LMNA (1.00) LMNAALDH1A1MAPK1THRBTSHR
Metronidazole SCHEMBL9482744 0.90 LMNA (1.00) LMNAALDH1A1MAPK1THRBTSHR
Metronidazole SCHEMBL9481347 0.90 LMNA (1.00) LMNAALDH1A1MAPK1THRBTSHR
Metronidazole SCHEMBL9455119 0.90 LMNA (1.00) LMNAALDH1A1MAPK1THRBTSHR
SCHEMBL28927348 0.90 LMNA (0.76) LMNAALDH1A1MAPK1THRBTSHR
Metronidazole SCHEMBL5595814 0.89 LMNA (0.97) LMNAALDH1A1MAPK1THRBTSHR
Metronidazole SCHEMBL8675069 0.89 LMNA (0.97) LMNAALDH1A1MAPK1THRBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025076059-A1 ROCAGLATE DERIVATIVES AND USES THEREOF TRUSTEES OF BOSTON UNIVERSITY (US) 2025-04-10 — — WO claimed
US-20250032455-A1 NITROIMIDAZOLE FORMULATIONS IRP Health Pty Ltd (AU) 2025-01-30 — — US claimed
US-12171748-B2 Nitroimidazole formulations IRP Health Pty Ltd (AU) 2024-12-24 — — US claimed
CN-115417820-B Chemical synthesis method of anti-anaerobe drug metronidazole 潍坊富邦药业有限公司 2024-03-29 — — CN claimed
US-20210220335-A1 NITROIMIDAZOLE FORMULATIONS IRP Health Pty Ltd (AU) 2021-07-22 — — US claimed
CN-108051507-B Method for analyzing residual veterinary drugs in mutton 新疆畜牧科学院畜牧业质量标准研究所（新疆维吾尔自治区种羊与羊毛羊绒质量安全监督检验中心） 2020-10-09 — — CN claimed
CN-107817306-A Method for simultaneously detecting 64 veterinary drug residues in aquatic product 中山出入境检验检疫局检验检疫技术中心 2018-03-20 — — CN claimed
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2017-10-12 — — US claimed
CN-105699565-B Detect the method and liquid matter database of left drug in animal-derived food 山东出入境检验检疫局检验检疫技术中心 2017-09-22 — — CN claimed
CN-104880529-B Detect method and the liquid matter data base of left drug in animal-derived food 山东出入境检验检疫局检验检疫技术中心 2016-08-31 — — CN claimed
EP-0324691-B1 PROCESS FOR THE PREPARATION OF 1-HYDROXYALKYL-5-NITRO-IMIDAZOLES RHONE-POULENC SANTE (FR) 1991-12-27 — — EP claimed
CN-1055536-A The preparation method of 1-hydroxyalkyl-5-nitroimidazole RHONE POULENC RORER SA (FR) 1991-10-23 — — CN claimed
WO-1991013877-A1 PROCESS FOR PREPARING HYDROXYALKYL-1 NITRO-5 IMIDAZOLES RHONE-POULENC RORER S.A. (FR) 1991-09-19 — — WO claimed
US-4925951-A Process for preparing 1-hydroxyalkyl-2-methyl-5-nitroimidazoles RHONE-POULENC SANTE (FR) 1990-05-15 — — US claimed
US-4925952-A Process for preparing 1-hydroxyalkyl-5-nitroimidazoles RHONE-POULENC SANTE (FR) 1990-05-15 — — US claimed
CN-1035289-A The preparation method of 1-hydroxyalkyl-2-methyl-5-nitro imidazoles RHONE POULENC SANTE (FR) 1989-09-06 — — CN claimed
CN-1035288-A The preparation method of 1-hydroxyalkyl-5-nitroimidazole RHONE POULENC SANTE (FR) 1989-09-06 — — CN claimed
EP-0325513-A1 Process for the preparation of 1-hydroxyalkyl-2-methyl-5-nitro-imidazoles RHONE-POULENC SANTE (FR) 1989-07-26 — — EP claimed
EP-0324691-A1 Process for the preparation of 1-hydroxyalkyl-5-nitro-imidazoles RHONE-POULENC SANTE (FR) 1989-07-19 — — EP claimed
CN-1031648-A Prevent mean that elastomeric material is made and manufacture method thereof HUTCHINSON (FR) 1989-03-15 — — CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210220335-A1 NITROIMIDAZOLE FORMULATIONS PHB1, COX5B, CYP3A5 LMNA 3271/4885ALDH1A1 3471/4885MAPK1 3643/4885
US-12171748-B2 Nitroimidazole formulations PHB1, COX5B, CYP3A5 LMNA 3271/4885ALDH1A1 3471/4885MAPK1 3643/4885
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS LMNA 2337/4885ALDH1A1 840/4885MAPK1 3157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.